Taiwan's FDA Authorizes Maryland's COVID-19 Vaccine

The Taiwan Food and Drug Administration (FDA) recently granted emergency use authorization for the Novavax COVID-19 vaccine for adults. Local media reported Taiwan FDA experts agreed to approve Novavax's Nuvaxovid™, the first protein-based vaccine per Taiwan's pharmaceutical laws, on June 17, 2022.

Taiwan's Minister of Health and Welfare Chen Shih-chung confirmed in April 2022 that Taiwan would receive about 2 million Nuvaxovid vaccines through the global vaccine sharing initiative COVAX.

Additionally, the Australian Therapeutic Goods Administration (TGA) granted provisional registration of Nuvaxovid as a booster in individuals aged 18 and over on June 13, 2022.

The TGA granted provisional registration in January 2022 for use of Nuvaxovid for adults.

On June 7, 2022, the U.S. FDA's Vaccine Committee voted to endorse Novavax's COVID19 vaccine authorization. 

As of June 21, 2022, the U.S. FDA continues reviewing Novavax's authorization request.

Novavax Inc.'s vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. 

This protein-based COVID-19 vaccine was designed in Gaithersburg, Maryland, is WHO authorized, and has been distributed in over 100 countries.

Note: This news was manually curated for mobile readership.